ArticleFood science & nutrition2025
Grape Seed Proanthocyanidins Protect Against Diabetic Retinopathy in Mice.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Special Issue: Molecular Mechanisms and Treatment of Retinal Diseases.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Grape seed proanthocyanidins (GSP), well-known dietary nutrients for public health, have been reported to alleviate diabetic retinopathy, but the underlying mechanisms remain largely unknown. Eight-week-old C57BL/6 mice were used. They were fed a high-fat diet and intraperitoneally injected with 50 mg/kg streptozotocin for five consecutive days to induce diabetes. One week later, 500 mg/kg GSP was given as a dietary supplement for 12 consecutive weeks in diabetic mice. Retinal degeneration, oxidative stress, and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway were assessed. GSP significantly reduced body weight and fasting blood glucose in diabetic mice. Diabetic retinopathy-impaired thickness of retina was also increased by GSP supplementation. Moreover, the expressions of vascular endothelial growth factor and glial fibrillary acidic protein induced by diabetic retinopathy were remarkably reduced by GSP. Furthermore, diabetic retinopathy-provoked oxidative stress, including over-production of reactive oxygen species and malondialdehyde, and attenuated activities of superoxide dismutase and catalase were all restored by GSP. Additionally, GSP also activated the Nrf2 signaling pathway, which was inhibited by diabetic retinopathy. These findings demonstrate that GSP ameliorates diabetic retinopathy by reducing oxidative stress, in which the Nrf2 signaling pathway is likely involved. This suggests that GSP might serve as a potential retina-protective candidate for diabetic retinopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.